hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06383585, orgStudyIdInfo id: 24-001367, briefTitle: 3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: GE Healthcare, descriptionModule briefSummary: This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI., conditionsModule conditions: Inflammatory Arthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: oZTEo, outcomesModule primaryOutcomes measure: The binary (yes/no) presence of bony erosions as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence., secondaryOutcomes measure: The number of erosions (continuous) as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06383572, orgStudyIdInfo id: 2024-0196, secondaryIdInfos id: NCI-2024-03505, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-31, primaryCompletionDateStruct date: 2027-04-01, completionDateStruct date: 2029-04-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS., conditionsModule conditions: Lymphodepleting Chemotherapy, conditions: Myeloid Malignancies, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Cyclophosphamide, interventions name: Fludarabine phosphate, interventions name: Decitabine, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Jeremy Ramdial, MD, role: CONTACT, phone: 713-745-0146, email: jlramdial@mdanderson.org, contacts name: Jeremy Ramdial, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06383559, orgStudyIdInfo id: TJMUCH-GI-GC07, briefTitle: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2026-07-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: This is a multi-center, prospective, open label phase 2 study evaluating the safety and efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab (anti-PD-1 antibody) and Lenvatinib in the treatment of advanced AFP-positive gastric cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. Previous phase 1 dose escalation study (TJMUCH-GI-GC002) has demonstrated that such combinational pattern was well tolerated with promising efficacy. In this study, patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/ m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with Sintilimab (\>=60kg, 200 mg; \<60kg, 3mg/kg; intravenous infusion, every 3 weeks) plus Lenvatinib (determined from previous phase 1 study, 16mg, orally once a day). Patients received regular and periodic reviews, with imaging evaluations every 6 weeks. Safety will be evaluated by AE and laboratory tests., conditionsModule conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Lenvatinib and Sintilimab, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: OS, secondaryOutcomes measure: PFS, otherOutcomes measure: AE, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Medical University Cancer Institute and Hospital, status: RECRUITING, city: Tianjin, state: Tianjin, country: China, contacts name: Ting Deng, MD, role: CONTACT, phone: 022-23340123, phoneExt: 1053, email: xymcdengting@126.com, contacts name: Yi Ba, MD, role: CONTACT, phone: 022-23340123, phoneExt: 1053, email: bayi@tjmuch.com, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06383546, orgStudyIdInfo id: XHEC-C-2024-053-1, briefTitle: Artificial Intelligence-enabled ECG Detection of Congenital Heart Disease in Children: a Novel Diagnostic Tool, acronym: AI-ECG-CHD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, class: OTHER, descriptionModule briefSummary: Congenital heart disease (CHD) is the most common congenital disease in children. The early detection, diagnosis and treatment of CHD in children is of great significance to improve the prognosis and reduce the mortality of children, but the current screening methods have limitations. Electrocardiogram (ECG), as an economical and rapid means of heart disease detection, has a very important value in the auxiliary diagnosis of CHD.Big data and deep learning technologies in artificial intelligence (AI) have shown great potential in the medical field. The advent of the big data era provides rich data resources for the in-depth study of CHD ECG signals in children. The development of deep learning technology, especially the breakthrough in the field of image recognition, provides a strong technical support for the intelligent analysis of electrocardiogram. The particularity of children electrocardiogram requires the development of a special algorithm model. At present, the research on the application of deep learning models to identify children's electrocardiograms is limited, and the training and verification from large data sets are lacking. Based on the Chinese Congenital Heart Disease Collaborative Research Network, this project aims to integrate data and deep learning technology to develop a set of intelligent electrocardiogram assisted diagnosis system (CHD-ECG AI system) suitable for children with CHD, so as to improve the early detection rate of CHD and improve the efficiency of congenital heart disease screening., conditionsModule conditions: Artificial Intelligence, conditions: Electrocardiogram, conditions: Deep Learning, conditions: Congenital Heart Disease in Children, conditions: Diagnosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 30000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Large-scale ECG database for children, primaryOutcomes measure: Artificial intelligence-assisted electrocardiogram model for CHD in Children, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, status: RECRUITING, city: Shanghai, state: Shanghai, country: China, contacts name: Sun Jing, MD, role: CONTACT, phone: 15618497517, email: sunjing02@xinhuamed.com.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06383533, orgStudyIdInfo id: IRB-2023-385, briefTitle: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Zhejiang Cancer Hospital, class: OTHER, descriptionModule briefSummary: It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma, conditionsModule conditions: Bile Duct Adenocarcinoma Non-Resectable, conditions: HER2 Gene Mutation, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Disitamab Vedotin Plus Cadonilimab, outcomesModule primaryOutcomes measure: Objective response rate(ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Incidence of Treatment-Emergent 3/4 Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310022, country: China, contacts name: Jieer Ying, Doctor, role: CONTACT, phone: 13858195803, email: hzyingjieer@163.com, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06383520, orgStudyIdInfo id: XLan-0415, briefTitle: Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-30, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Wuhan Union Hospital, China, class: OTHER, descriptionModule briefSummary: This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv), to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens., conditionsModule conditions: Malignant Neoplasm of Liver, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: 68Ga-aGPC3-scFv/Fab, outcomesModule primaryOutcomes measure: Visual and standardized uptake values assessment of lesions and biodistribution, secondaryOutcomes measure: Radioactivity in the blood and urine samples, secondaryOutcomes measure: Concentration of tumor markers (e.g., APF) in participants' blood, secondaryOutcomes measure: Pathological sections of tumour tissue, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China, Hubei Province, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430022, country: China, contacts name: Xiaoli Lan, PhD, role: CONTACT, phone: +86-027-83692633, email: lxl730724@hotmail.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06383507, orgStudyIdInfo id: CHT101, briefTitle: A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2027-04-21, completionDateStruct date: 2029-04-21, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns., conditionsModule conditions: Metastatic Tumor, conditions: Advanced Solid Tumor, conditions: Renal Cell Carcinoma, conditions: Ovarian Cancer, conditions: Cervix Cancer, conditions: Head and Neck Squamous Cell Carcinoma, conditions: Nasopharyngeal Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: CHT101, outcomesModule primaryOutcomes measure: Incidence of Adverse events after CD70 UCAR-T cells infusion (Safety and Tolerability), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Objective response rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06383494, orgStudyIdInfo id: IRB-2024-356（IIT）, briefTitle: GMA-TulipTM, i-gelTM and the LMA-SupremeTM (LMA-S) Devices in Airway Management, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Zhejiang Cancer Hospital, class: OTHER, descriptionModule briefSummary: Patients were randomly assigned to three extraglottic airway (EGA) devices groups for airway management after anesthesia induced. Fiberoptic bronchoscope (FB) guided glottic exposure grading was performed and other airway management quality was recorded., conditionsModule conditions: Anesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 276, type: ESTIMATED, armsInterventionsModule interventions name: LMA supreme group, interventions name: I-gel group, interventions name: GMA-Tulip, outcomesModule primaryOutcomes measure: Glottic exposure grading, secondaryOutcomes measure: Peak inspiratory pressures, secondaryOutcomes measure: Pharyngalgia, secondaryOutcomes measure: Bleeding, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310022, country: China, contacts name: Jiangling Wang, Ph. D, role: CONTACT, phone: +86 571 88122106, email: wangjl@zjcc.org.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06383455, orgStudyIdInfo id: Observational, briefTitle: Effects of Smoking on Clinical and Microbiological Response in Individuals With Periodontitis, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-09-15, primaryCompletionDateStruct date: 2019-02-01, completionDateStruct date: 2019-03-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Trakya University, class: OTHER, descriptionModule briefSummary: This study aimed to compare the distribution of subgingival periodontal pathogens following non-surgical periodontal therapy in smoking and non-smoking people with periodontitis. The main question it aims to answer is:- Does smoking affect the results of non-surgical periodontal treatment on subgingival flora in participants with periodontal disease?Researchers performed non-surgical periodontal therapy on 48 participants with stage III/IV periodontitis and recorded clinical measurements. They obtained subgingival plaque samples from periodontal pockets at the onset and after four weeks of treatment, determining the level of periodontopathogens using a polymerase chain reaction-based method., conditionsModule conditions: Periodontitis, conditions: Smoking Habit, conditions: Subgingival Plaque, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 48, type: ACTUAL, armsInterventionsModule interventions name: Non-surgical periodontal therapy, outcomesModule primaryOutcomes measure: Change in levels of periodontopathogens in subgingival plaque after non-surgical periodontal therapy in smokers and non-smokers with stage 3/4 periodontitis, secondaryOutcomes measure: Change in clinical attachment level (CAL), secondaryOutcomes measure: Change in probing depth (PD), secondaryOutcomes measure: Change in gingival index (GI) scores, secondaryOutcomes measure: Change in plaque index (PI) scores, secondaryOutcomes measure: Change in Bleeding on Probing (BOP), eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Trakya University, city: Edirne, zip: 22030, country: Turkey, geoPoint lat: 41.67719, lon: 26.55597, hasResults: False
protocolSection identificationModule nctId: NCT06383442, orgStudyIdInfo id: N202103041, briefTitle: HIIT on Overweight Middle-aged Adults, acronym: HIIT, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-25, primaryCompletionDateStruct date: 2023-07-31, completionDateStruct date: 2023-11-22, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Taipei Medical University, class: OTHER, descriptionModule briefSummary: 36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss., conditionsModule conditions: Overweight or Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants were evenly distributed according to a counterbalanced design and divided into three different groups by the body fat percentage of subjects: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest), 3. Control group. Target intensities of each interval bout, exercise and rest (Ex./R.), were 85-90% VO2peak/65-70% VO2peak zones, respectively., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: L-HIIT, interventions name: M-HIIT, outcomesModule primaryOutcomes measure: Aerobic Capacity Test, primaryOutcomes measure: Aerobic Capacity Test, primaryOutcomes measure: Anti-fatigue performance, primaryOutcomes measure: skinfold thickness, primaryOutcomes measure: Body composition_body fat, secondaryOutcomes measure: Glucose, secondaryOutcomes measure: Triglycerides, secondaryOutcomes measure: low-density lipoprotein (LDL), secondaryOutcomes measure: high-density lipoprotein (HDL), secondaryOutcomes measure: creatine kinase (CK) level, secondaryOutcomes measure: C-reactive protein (CRP), secondaryOutcomes measure: tumor necrosis factor (TNF)-R1, secondaryOutcomes measure: TNF-R2, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei Medical University, city: Taipei, zip: 110, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False